SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

INSIDE INFORMATION – 2021 RESULTS FORECAST

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") as well as the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Please also refer to the overseas regulatory announcement of the Company dated 28 January 2022.

The principal consolidated financial data of the Company for the year ended 31 December 2021 (the "**Reporting Period**") set out in this announcement is prepared in accordance with the China Accounting Standards for Business Enterprises, and is only preliminary estimated data, and has not been audited. This results forecast is prepared pursuant to the relevant regulations of the Shanghai Stock Exchange and the People's Republic of China. The audited data is subject to the financial data to be disclosed in the 2021 annual report of the Company. Shareholders and investors are advised to exercise caution when dealing in the shares of the Company.

I. RESULTS FORECAST FOR THE REPORTING PERIOD

(I) Results forecast period

From 1 January 2021 to 31 December 2021

(II) Results forecast

According to preliminary calculations by the financial department of the Company,

1. it is estimated that the operating revenue for 2021 would be approximately RMB4,014 million, representing an increase of approximately RMB2,419.1034 million compared with the same period of the previous year or a year-on-year increase of approximately 151.68%.

2. it is estimated that the research and development ("**R&D**") expenses for 2021 would be approximately RMB2,075 million, representing an increase of approximately RMB296.9770 million compared with the same period of the previous year or a year-on-year increase of approximately 16.70%.

3. it is estimated that the net loss attributable to the owners of the parent company for 2021 would be approximately RMB736 million, representing a decrease in loss of approximately RMB932.6068 million compared with the same period of the previous year or a year-on-year decrease in loss of approximately 55.89%.

4. it is estimated that the net loss attributable to the owners of the parent company after deducting non-recurring gains and losses for 2021 would be approximately RMB921 million, representing a decrease in loss of approximately RMB787.8250 million compared with the same period of the previous year or a year-on-year decrease in loss of approximately 46.10%.

(III) This results forecast has not been audited by certified public accountant.

II. RESULTS FOR THE SAME PERIOD IN THE PREVIOUS YEAR

(I) In 2020, the Company recorded operating revenue of RMB1,594.8966 million.

(II) The R&D expenses for 2020 were RMB1,778.0230 million.

(III) Net loss attributable to owners of the parent company for 2020 was RMB1,668.6068 million. Net loss attributable to owners of the parent company after deducting non-recurring gains and losses for 2020 was RMB1,708.8250 million.

III. MAIN REASONS FOR THE CHANGES IN RESULTS FOR THE REPORTING PERIOD

(I) It is estimated that the Company's operating revenue would increase significantly during the Reporting Period, which the Company considers to be mainly attributable to sales revenue from commercialization of the domestic market of its core product Toripalimab Injection (trade name: 拓益® (TUOYI®)), the substantial increase in licensing income, and the newly recorded royalty income. In particular, with respect to licensing income and royalty income:

1. pursuant to the research collaboration and license agreement entered into between the Company and Eli Lilly and Company ("**Lilly**"), by virtue of the rapid progress of the cooperation, all milestone events agreed upon in the overseas licensing of etesevimab (JS016/LY-CoV016) to Lilly have been completed. In addition, the Company entered into an exclusive license and commercialization agreement with Coherus BioSciences, Inc., pursuant to which both parties agreed to carry out in-depth cooperation in the field of tumor immunotherapy in the United States and Canada. Based on the above two cooperation projects, the Company's licensing income is estimated to increase significantly during the Reporting Period;

2. in view of the overseas development of the COVID-19 pandemic, As of the end of the Reporting Period, etesevimab and bamlanivimab (LY-CoV555) administered together has obtained emergency use authorizations in over 15 countries and regions. Along with the commercialization of such therapy, the Company would record new royalty income during the Reporting Period.

(II) In 2021, the expected net loss attributable to the owners of the parent company is mainly due to the continuous increase in the Company's investment in ongoing and reserved R&D projects, and the operating revenue excluding expenses incurred in respect of product marketing and daily operation was not yet sufficient to fully cover the Company's R&D investment. During the Reporting Period, it is estimated that the Company's R&D expenses would be approximately RMB2,075 million, representing a year-on-year increase of approximately 16.70%. The Company continuously enriched its product pipeline, explored the combination therapy of drugs, accelerated the development of existing clinical projects and reserved R&D projects, as well as accelerated the development of a number of product pipelines with first-in-class or differentiated development value during the Reporting Period, leading to a further increase in R&D expenses of the Company. During the Reporting Period, more than 10 self-developed or cooperative development projects of the Company have been approved for clinical trials; three new indications for toripalimab have been approved for marketing by the National Medical Products Administration (the "**NMPA**"); two supplemental new drug applications have been accepted by the NMPA. As of the date of this announcement, the Company's R&D pipeline has expanded to over 45 pipeline assets, covering five major therapeutic areas. Amongst them, there are two assets (toripalimab and etesevimab) at the stage of commercialization and one asset (adalimumab) at the stage of New Drug Application. In addition to the above assets, there are over 20 assets at the stage of clinical trials.

In summary, while the Company is expected to record a net loss for 2021, the net loss of the Company for 2021 is expected to record a greater decline as compared to the same period in the previous year.

IV. RISK WARNING

The Company is not aware of any material uncertainties that will affect the accuracy of the content of this results forecast.

V. OTHER MATTERS

The above estimated data is only a preliminary estimation. Please refer to the audited 2021 annual report to be officially published by the Company for specific and accurate financial information. Shareholders and investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 28 January 2022

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng and Mr. Li Cong as executive directors; Dr. Wu Hai, Mr. Tang Yi and Mr. Lin Lijun as non-executive directors; and Dr. Chen Lieping, Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Feng Xiaoyuan as independent non-executive directors.

* *For identification purposes only*